Overview

Natural killer T cells, commonly abbreviated NKT cells, are a small but functionally important subset of T lymphocytes. They combine properties of conventional T cells and natural killer (NK) cells: like T cells they bear a T cell receptor and develop in the thymus, and like NK cells they often express surface proteins associated with innate cytotoxicity. NKT cells are relatively rare in the bloodstream (often cited around 0.1% of peripheral T cells) but are enriched in certain tissues and have outsized influence on immune responses.

Distinctive features and classification

NKT cells are defined by their ability to recognize lipid and glycolipid antigens presented by the nonpolymorphic antigen‑presenting molecule CD1d, rather than the peptide‑MHC complexes that stimulate most T cells. A well‑studied subset, often called invariant NKT (iNKT) cells, expresses a semi‑invariant TCR alpha chain (humans commonly Vα24‑Jα18) and responds strongly to the model glycolipid alpha‑galactosylceramide. Other NKT populations (sometimes grouped as type II NKT) show more TCR diversity and different antigen specificities.

Typical surface markers include CD3 together with receptors associated with NK cells; in research contexts markers such as NK1.1 (in mice) or CD161 (in humans) are often used. Transcription factors like PLZF contribute to their innate‑like rapid response program.

Functions and mechanisms

NKT cells bridge innate and adaptive immunity. On activation they can secrete large amounts of cytokines (both pro‑inflammatory and regulatory) within hours, influencing downstream T cell, B cell and myeloid responses. They can kill infected or transformed cells directly and help shape responses to microbial lipids, tumor antigens and self‑antigens.

  • Antigen recognition: lipid/glycolipid antigens presented by CD1d.
  • Effector outputs: rapid cytokine release and cytotoxicity.
  • Subsets: iNKT (invariant) and more diverse type II NKT cells.

Biological and clinical significance

NKT cells play roles in antimicrobial defenses, tumor immunosurveillance, allergy and modulation of autoimmunity. They are implicated in responses to organisms that present lipid antigens, including mycobacterial species. Dysfunction or altered numbers of NKT cells have been associated with autoimmune conditions, metabolic inflammation and cancer progression in experimental and clinical observations.

Because of their rapid cytokine secretion and ability to influence multiple arms of immunity, NKT cells are a focus of translational research. Strategies include harnessing iNKT agonists as vaccine adjuvants, targeting NKT pathways to boost anti‑tumor immunity, or modulating their activity to reduce harmful inflammation.

For broader context see the entries on T cells and contrasts with natural killer (NK) cells. Distribution in blood and tissues is discussed in sources that address peripheral blood lymphocyte populations. NKT recognition of microbial lipids is relevant for pathogens such as mycobacteria and diseases like tuberculosis. Reviews of clinical correlations discuss links with autoimmune diseases, cancer, and allergic conditions including asthma. The central role of rapid mediator release is summarized under cytokines.